Edition:
United States

Accuray Inc (ARAY.OQ)

ARAY.OQ on NASDAQ Stock Exchange Global Select Market

4.05USD
22 May 2017
Change (% chg)

-- (--)
Prev Close
$4.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
169,962
52-wk High
$6.39
52-wk Low
$3.85

Latest Key Developments (Source: Significant Developments)

Accuray reports prelim data from phase I trial of breast cancer cure treated with Cyberknife System
Tuesday, 2 May 2017 07:30am EDT 

May 2 (Reuters) - Accuray Inc :Prelim data from phase I trial evaluating adjuvant stereotactic partial breast irradiation in early stage breast cancer patients treated with Cyberknife System.S-PBI provides more convenient treatment option than hypofractionated whole-breast irradiation with no compromise in tolerability or short-term efficacy.  Full Article

Accuray Q3 loss per share $0.06
Thursday, 27 Apr 2017 04:01pm EDT 

April 27 (Reuters) - Accuray Inc :Q3 loss per share $0.06.Q3 revenue $97.3 million.Accuray Inc - gross product orders totaled $83.8 million for 2017 fiscal Q3 compared to $56.4 million for prior fiscal year period.Accuray Inc qtrly ending product backlog was $450.0 million, approximately 21 percent higher than backlog at end of prior fiscal year Q3.Accuray Inc - 2017 outlook for gross orders growth of approximately five percent is reaffirmed.Accuray Inc - revenue for fiscal year is now expected to range between $380.0 million and $390.0 million.Accuray Inc - 2017 adjusted EBITDA is now expected to range between $22.0 million and $26.0 million.FY 2017 revenue view $407.2 million -- Thomson Reuters I/B/E/S.  Full Article

Accuray on March 10, co entered into an amendment to financing agreement dated as of Jan. 11, 2016
Friday, 10 Mar 2017 05:50pm EST 

Accuray Inc : On March 10, co entered into an amendment to financing agreement dated as of January 11, 2016 - sec filing . Accuray Inc - second amendment requires company to obtain a letter of credit in face amount of $12.5 million for benefit of administrative agent . Accuray Inc - second amendment makes certain related amendments to debt and lien covenants and financial ratio definitions .Accuray - second amendment increased interest rate margins under financing agreement by 0.50% until certain specified conditions are met.  Full Article

Accuray posts Q2 loss per share $0.11
Tuesday, 31 Jan 2017 04:01pm EST 

Accuray Inc : Q2 ending product backlog was $426.2 million, approximately 16 percent higher . Q2 loss per share $0.11 . Q2 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S . Qtrly total revenue was $87.5 million compared to $108.9 million in prior fiscal year Q2 . Reaffirming guidance originally provided on August 17, 2016 for fiscal year 2017 for all metrics except operating expenses . FY2017 earnings per share view $-0.19, revenue view $409.4 million -- Thomson Reuters I/B/E/S .Q2 revenue view $90.4 million -- Thomson Reuters I/B/E/S.  Full Article

Accuray reports Q4 loss per share $0.09
Wednesday, 17 Aug 2016 04:01pm EDT 

Accuray Inc : Accuray reports fourth quarter and fiscal 2016 financial results . Q4 loss per share $0.09 . Q4 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S . Q4 revenue $95 million versus i/b/e/s view $99 million . Sees FY 2017 revenue $410 million to $420 million . Backlog increased 8 percent year-over-year to $405.9 million in quarter . Sees fy 2017 adjusted ebitda $32.0 million to $38.0 million . FY2017 revenue view $431.8 million -- Thomson Reuters I/B/E/S . Qtrly gross orders increased 12 percent over prior year period to $95.4 million . Sees FY 2017 backlog and gross orders growth of approximately 5 percent .Approximately 55 percent of revenue and 60 percent of gross orders are anticipated in second half of fiscal year in fy 2017.  Full Article

Accuray CE marks its radixact system
Tuesday, 9 Aug 2016 06:30am EDT 

Accuray Inc : CE marked its radixact treatment delivery system, Accuray precision treatment planning system and IDMS data management system . Platform will now be available in certain markets in European Union (EU) .Have shipped first commercially released radixact system to a site in U.S. and expect first eu shipment during fiscal Q1 2017.  Full Article

Accuray retires remaining 3.75 percent convertible debt
Tuesday, 2 Aug 2016 06:30am EDT 

Accuray Inc : Retires remaining 3.75 percent convertible debt . Says 2016 notes were settled on August 1 for $37.3 million, which included $36.6 million in principal and $0.7 million in accrued interest .Says settled remaining principal amount and accrued interest thereon of 3.75 percent convertible senior notes.  Full Article

Accuray receives 510(K) FDA clearance for image-guided radiation therapy
Monday, 27 Jun 2016 06:30am EDT 

Accuray: Accuray receives 510(k) FDA clearance for the Radixact image-guided radiation therapy platform and integrated software .Will initiate commercial release of Radixact system late in Q1 of fiscal year 2017.  Full Article

Accuray sees FY 2016 backlog about $405 mln
Tuesday, 24 May 2016 04:23pm EDT 

Accuray Inc :Accuray Inc sees FY 2016 backlog about $405 million - SEC filing.  Full Article

Accuray Inc Reaffirms FY 2016 guidance
Thursday, 28 Jan 2016 04:03pm EST 

Accuray Inc:Reaffirmed previously provided financial guidance For Fy 2016.Says Fy 2016 Total revenue is expected to be between $395 million to $410 million and adjusted EBITDA is expected to range between $25 million to $35 million.Accuray continues to expect Fy 2016 gross orders for Fy 2016 will be approximately $295 million, which would represent a 10 percent increase year over year.  Full Article

More From Around the Web

BRIEF-Accuray reports prelim data from phase I trial of breast cancer cure treated with Cyberknife System

* Prelim data from phase I trial evaluating adjuvant stereotactic partial breast irradiation in early stage breast cancer patients treated with Cyberknife System